Gilead Sciences
Price
Price
CHART BY
Historical dividends and forecast
Gilead Sciences has so far distributed $2.31 in 2024. The next dividend will be paid on 30.12.2024
CHART BY
Frequently asked questions
What is Gilead Sciences's market capitalization?
What is Gilead Sciences's Price-to-Earnings (P/E) ratio?
What is the Earnings Per Share (EPS) for Gilead Sciences?
What are the analyst ratings and target price for Gilead Sciences's stock?
What is Gilead Sciences's revenue over the trailing twelve months?
Is Gilead Sciences paying dividends?
What is the EBITDA for Gilead Sciences?
What is the free cash flow of Gilead Sciences?
How many employees does Gilead Sciences have, and what sector and industry does it belong to?
What is the free float of Gilead Sciences's shares?
Financials
- Market Cap
- $115.37B
- EPS (TTM)
- $0.0887
- Free Float
- 1.24B
- P/E ratio (TTM)
- 1,043.63
- Revenue (TTM)
- $28.27B
- EBITDA (TTM)
- $13.35B
- Free Cashflow (TTM)
- $9.43B
Pricing
- 1D span
- $90.24$93.29
- 52W span
- $62.07$98.90
Analyst Ratings
The price target is $99.21 and the stock is covered by 32 analysts.
Buy
18
Hold
14
Sell
0
Information
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
- Employees
- 18,000
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- ISIN
- US3755581036
- Primary Ticker
- GILD